Individual risk evaluation for local recurrence and distant metastasis in Ewing sarcoma: A multistate model A multistate model for Ewing sarcoma

被引:19
|
作者
Bosma, S. E. [1 ]
Rueten-Budde, A. J. [2 ]
Lancia, C. [2 ]
Ranft, A. [3 ,4 ]
Dirksen, U. [3 ,4 ]
Krol, A. D. [5 ]
Gelderblom, H. [6 ]
van de Sande, M. A. J. [1 ]
Dijkstra, P. D. S. [1 ]
Fiocco, M. [2 ,7 ]
机构
[1] Leiden Univ, Med Ctr, Dept Orthoped, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands
[2] Leiden Univ, Math Inst, Leiden, Netherlands
[3] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Sarcoma Ctr,German Canc Consortium,Pediat 3, Essen, Germany
[4] German Canc Consortium DKTK, Essen, Germany
[5] Leiden Univ, Med Ctr, Dept Radiotherapy, Leiden, Netherlands
[6] Leiden Univ, Med Ctr, Dept Med Oncol, Leiden, Netherlands
[7] Leiden Univ, Med Ctr, Med Stat Biomed Data Sci, Leiden, Netherlands
基金
欧盟第七框架计划;
关键词
Ewing sarcoma; multistate model; personalized medicine; prediction; survival; PROGNOSTIC-FACTORS; CHEMOTHERAPY; TUMORS; BONE; EXPERIENCE; SURVIVAL; ADJUVANT; SURGERY; THERAPY; PROGRAM;
D O I
10.1002/pbc.27943
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background We investigated the effects of surgical margins, histological response, and radiotherapy on local recurrence (LR), distant metastasis (DM), and survival in Ewing sarcoma. Procedure Disease evolution was retrospectively studied in 982 patients with Ewing sarcoma undergoing surgery after chemotherapy using a multistate model with initial state surgery, intermediate states LR, pulmonary metastasis (DMpulm), other DM +/- LR (DMother), and final state death. Effect of risk factors was estimated using Cox proportional hazard models. Results The median follow-up was 7.6 years (95% CI, 7.2-8.0). Risk factors for LR are pelvic location, HR 2.04 (1.10-3.80), marginal/intralesional resection, HR 2.28 (1.25-4.16), and radiotherapy, HR 0.52 (0.28-0.95); for DMpulm the risk factors are <90% necrosis, HR 2.13 (1.13-4.00), and previous pulmonary metastasis, HR 4.90 (2.28-8.52); for DMother are 90% to 99% necrosis, HR 1.56 (1.09-2.23), <90% necrosis, HR 2.66 (1.87-3.79), previous bone/other metastasis, HR 3.08 (2.03-4.70); and risk factors for death without LR/DM are pulmonary metastasis, HR 8.08 (4.01-16.29), bone/other metastasis, HR 10.23 (4.90-21.36), and <90% necrosis, HR 6.35 (3.18-12.69). Early LR (0-24 months) negatively influences survival, HR 3.79 (1.34-10.76). Once DMpulm/DMother arise only previous bone/other metastasis remain prognostic for death, HR 1.74 (1.10-2.75). Conclusion Disease extent and histological response are risk factors for progression to DM or death. Tumor site and surgical margins are risk factors for LR. If disease progression occurs, previous risk factors lose their relevance. In case of isolated LR, time to recurrence is important for decision-making. Radiotherapy seems protective for LR especially in pelvic/axial. Low percentages of LR in extremity tumors and associated toxicity question the need for radiotherapy in extremity Ewing sarcoma.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Developing a Prognostic Model for Localized Ewing Sarcoma Family of Tumors: A Single Institutional Experience of 224 Cases Treated With Uniform Chemotherapy Protocol
    Biswas, Bivas
    Rastogi, S.
    Khan, S. A.
    Shukla, N. K.
    Deo, S. V. S.
    Agarwala, S.
    Mohanti, B. K.
    Sharma, M. C.
    Vishnubhatla, Sreenivas
    Bakhshi, S.
    JOURNAL OF SURGICAL ONCOLOGY, 2015, 111 (06) : 683 - 689
  • [32] CORR Insights®: Can Multistate Modeling of Local Recurrence, Distant Metastasis, and Death Improve the Prediction of Outcome in Patients With Soft Tissue Sarcomas?
    Nystrom, Lukas M.
    CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2017, 475 (05) : 1436 - 1438
  • [33] Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model
    Minas, Tsion Zewdu
    Surdez, Didier
    Javaheri, Tahereh
    Tanaka, Miwa
    Howarth, Michelle
    Kang, Hong-Jun
    Han, Jenny
    Han, Zhi-Yan
    Sax, Barbara
    Kream, Barbara E.
    Hong, Sung-Hyeok
    Celik, Haydar
    Tirode, Franck
    Tuckermann, Jan
    Toretsky, Jeffrey A.
    Kenner, Lukas
    Kovar, Heinrich
    Lee, Sean
    Sweet-Cordero, E. Alejandro
    Nakamura, Takuro
    Moriggl, Richard
    Delattre, Olivier
    Ueren, Aykut
    ONCOTARGET, 2017, 8 (21) : 34141 - 34163
  • [34] Sensitive and Specific Detection of Ewing Sarcoma Minimal Residual Disease in Ovarian and Testicular Tissues in an In Vitro Model
    Chaput, Laure
    Greze, Victoria
    Halle, Pascale
    Radosevic-Robin, Nina
    Pereira, Bruno
    Veronese, Lauren
    Lejeune, Herve
    Durand, Philippe
    Martin, Guillaume
    Sanfilippo, Sandra
    Canis, Michel
    Kanold, Justyna
    Tchirkov, Andrei
    Brugnon, Florence
    CANCERS, 2019, 11 (11)
  • [35] The prognostic significance of surgical resection margins for local recurrence, distant metastasis, and overall survival in sarcoma
    Stauss, Ricarda
    Aigner, Alexander
    Richter, Alena
    Suero, Eduardo
    Altemeier, Anna
    Savov, Peter
    Ettinger, Max
    Omar, Mohamed
    JOURNAL OF SURGICAL ONCOLOGY, 2023, 128 (07) : 1160 - 1170
  • [36] Proliferation Index: A Continuous Model to Predict Prognosis in Patients with Tumours of the Ewing's Sarcoma Family
    Brownhill, Samantha
    Cohen, Dena
    Burchill, Sue
    PLOS ONE, 2014, 9 (08):
  • [37] Inhibiting Platelet-derived Growth Factor β Reduces Ewing's Sarcoma Growth and Metastasis in a Novel Orthotopic Human Xenograft Model
    Wang, Yong Xin
    Mandal, Deendayal
    Wang, Suizhau
    Hughes, Dennis
    Pollock, Raphael E.
    Lev, Dina
    Kleinerman, Eugenie
    Hayes-Jordan, Andrea
    IN VIVO, 2009, 23 (06): : 903 - 909
  • [38] Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma
    Gendy, Amir S.
    Lipskar, Aaron
    Glick, Richard D.
    Steinberg, Bettie M.
    Edelman, Morris
    Soffer, Samuel Z.
    JOURNAL OF PEDIATRIC SURGERY, 2011, 46 (01) : 108 - 114
  • [39] Age-related differences of oncological outcomes in primary extremity soft tissue sarcoma: a multistate model including 6260 patients
    Acem, Ibtissam
    Verhoef, Cornelis
    Rueten-Budde, Anja J.
    Grunhagen, Dirk J.
    van Houdt, Winan J.
    van de Sande, Michiel A. J.
    EUROPEAN JOURNAL OF CANCER, 2020, 141 : 128 - 136
  • [40] Modeling Stroma-Induced Drug Resistance in a Tissue-Engineered Tumor Model of Ewing Sarcoma
    Santoro, Marco
    Menegaz, Brian A.
    Lamhamedi-Cherradi, Salah-Eddine
    Molina, Eric R.
    Wu, Danielle
    Priebe, Waldemar
    Ludwig, Joseph A.
    Mikos, Antonios G.
    TISSUE ENGINEERING PART A, 2017, 23 (1-2) : 80 - 89